. Author manuscript; available in PMC: 2016 May 1.

Published in final edited form as: Cancer Chemother Pharmacol. 2015 Apr 23;75(5):1075–1087. doi: 10.1007/s00280-015-2737-4

Table 4.

Grade 3 and 4 toxicities in IP Nanotax^®, mGOG-172 and GOG-172 trials [14]

Toxicity	IP Nanotax^®, all doses (N = 21) number (%)	Frequency of Grade 3 or 4 toxicity in modified outpatient IV/IP regimen in mGOG-172, (N = 102) number (%)	Frequency of Grade 3 or 4 toxicity in IV/IP therapy group in GOG-172 (%)
Neutropenia	0	12 (12)	76
Thrombocytopenia	1 (5)	0	12
Gastrointestinal	9 (43)	8 (8)	46
Renal	1 (5)	2 (2)	7
Metabolic	3 (14)	5 (5)	27
Neurologic	0	6 (6)	19
Infection	5 (24)	2 (2)	16
Febrile neutropenia	0	0	–
Abdominal pain	4 (19)	3 (3)	–
Fatigue	4 (19)	2 (2)	18
IP port infection	1 (5)	2 (2)	18
IP port blocked	0	1 (1)	8
Treatment-related death	0	0	2